{
    "Trade/Device Name(s)": [
        "Dimension EXL LOCI BRAHMS Procalcitonin (PCT)",
        "Dimension\u00ae EXL\u2122 LOCI\u00ae BRAHMS Procalcitonin (PCT)"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics, Inc.",
    "510(k) Number": "K220262",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN150009",
        "K171338"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PRI",
        "PMT"
    ],
    "Summary Letter Date": "August 26, 2022",
    "Summary Letter Received Date": "January 31, 2022",
    "Submission Date": "January 26, 2022",
    "Regulation Number(s)": [
        "21 CFR 866.3215"
    ],
    "Regulation Name(s)": [
        "Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Procalcitonin (PCT)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (lithium heparin)",
        "Plasma (sodium heparin)",
        "Plasma (K2EDTA)",
        "Plasma (K3EDTA)"
    ],
    "Specimen Container(s)": [
        "Serum Separator Tube (SST)",
        "Rapid Serum Tube (RST)",
        "Lithium heparin tube",
        "Sodium heparin tube",
        "K2EDTA tube",
        "K3EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Dimension EXL integrated chemistry system with LOCI Module"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Chemiluminescent immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Dimension EXL LOCI BRAHMS Procalcitonin (PCT) assay for quantitative measurement of procalcitonin to aid sepsis assessment using chemiluminescent immunoassay on the Dimension EXL system",
    "Indications for Use Summary": "Quantitative measurement of procalcitonin in human serum and plasma as an aid in risk assessment for progression to severe sepsis/septic shock in ICU, cumulative 28-day mortality risk assessment, antibiotic therapy decision for suspected/confirmed lower respiratory tract infections, and antibiotic discontinuation for suspected/confirmed sepsis, used in conjunction with other laboratory findings and clinical assessments",
    "fda_folder": "Microbiology"
}